WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies and small molecules, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

15.07.2014: WILEX publishes Half-yearly Financial Report 2014. ...More

15.07.2014: WILEX AG successfully completes capital reduction.  ...More

Seite gelesen: 164098 | Heute: 268